Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05407025 · ClinicalTrials.gov registry record
Targeting Inflammation for Endometrial Cancer Prevention
A clinical trial of Endometrial Carcinoma, sponsored by Mayo Clinic.
- Active
- Registry status
- 191
- Enrollment target
- 2
- Study locations
NCT05407025: Active study of Endometrial Carcinoma, sponsored by Mayo Clinic.
NCT05407025 is a study of Endometrial Carcinoma that is active but no longer recruiting, run by Mayo Clinic. The registered enrollment target is 191 participants, below the 384-participant average among 27 other Endometrial Carcinoma trials with a reported enrollment target (50% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05407025, a study of Endometrial Carcinoma, is active but no longer recruiting, sponsored by Mayo Clinic.
- ACTIVE NOT RECRUITING
- Registry status
- 191 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study examines risk assessment and identifies prevention strategies for endometrial cancer. Collecting samples of blood and urine and risk assessments from patients with benign conditions or endometrial cancer may help doctors learn if there is a relationship between chronic inflammation and increase in risk for endometrial cancer.
Primary Outcome
Will compare eicosanoid and SPM levels by case-control status (women with endometrial carcinoma and women with non-cancerous conditions) in all patients with linear models, adjusted for age and body mass index (BMI) (and menstrual date, if needed).
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Questionnaire Administration
Study Locations (2)
Arizona
- Mayo Clinic in Arizona - Scottsdale
Florida
- Mayo Clinic in Florida - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 191 participants |
| Start Date | 2021-12-01 |
| Est. Completion | 2027-12-31 |
What the registry record for NCT05407025 still lists
NCT05407025 is an observational study that tracks outcomes without assigning an intervention. The registered 191 participants enrollment target is mid-sized for trials with a published cap, below the 384-participant average among 27 other Endometrial Carcinoma trials with a reported enrollment target (50% lower).
The record links to 1 condition, with Endometrial Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Biospecimen Collection is the first listed.
NCT05407025 reports a single indexed study location in Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT05407025 about?
NCT05407025 is a clinical study titled "Targeting Inflammation for Endometrial Cancer Prevention". This study examines risk assessment and identifies prevention strategies for endometrial cancer. Collecting samples of blood and urine and risk assessments from patients with benign conditions or endometrial cancer may help doctors learn if there is a relationship between chronic inflammation and in...
What is the current status of trial NCT05407025?
This trial is currently active not recruiting. The enrollment target is 191 participants. The study started on 2021-12-01. Estimated completion is 2027-12-31.
What conditions does trial NCT05407025 study?
This clinical trial studies the following conditions: Endometrial Carcinoma.
What interventions are being tested in trial NCT05407025?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Questionnaire Administration (OTHER).
Who is sponsoring clinical trial NCT05407025?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05407025 being conducted?
This trial has 2 study locations across Arizona, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05407025's enrollment target sits among peer trials
191 6th of 27 higher than 22 of 27 other Endometrial Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Endometrial Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Concurrent Laparoscopic Hysterectomy and Weight Loss Surgery in Obese Patients With Endometrial Carcinoma or Endometrial Intraepithelial Neoplasia
RECRUITING · NA
-
Screening and Staging of Benign vs Malignant Pelvic Abnormalities
RECRUITING
-
Non-Invasive Identification of Endometrial Cancer/Endometrial Atypical Hyperplasia With an AI-Based Classifier Applied to Transvaginal Ultrasound in Patients With Post-Menopausal Bleeding
RECRUITING
-
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
RECRUITING · Phase 3
-
Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer
RECRUITING · Phase 1
-
Comparison of Proton or Intensity Modulated Radiation Therapy After Surgery for Endometrial or Cervical Cancer
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04621435 · 191 participants · Phase 1
Imaging of Solid Tumors Using FAP-2286
- NCT06810544 · 191 participants · Phase 1
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
- NCT01492972 · 192 participants · Phase 3
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
- NCT01973881 · 192 participants
Quantitative MRI for Myelofibrosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI